echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > FDA Breakthrough Therapy Designation for Novel RSV Vaccine Prompts Broad Immune Response

    FDA Breakthrough Therapy Designation for Novel RSV Vaccine Prompts Broad Immune Response

    • Last Update: 2022-05-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 14, 2022, Bavarian Nordic announced that the U.


    RSV is a very common infectious agent, divided into two subtypes according to antigenicity: type A and type


    MVA-BN RSV is a vaccine candidate developed by Bavarian Nordic to prevent RSV and is currently targeting elderly individuals


    picture

    Image source: 123RF

    Last year the company announced results from a double-blind, placebo-controlled Phase 2 clinical trial


    In addition, another phase 2 clinical trial in 421 elderly subjects aged 55 years and older demonstrated that the vaccine was well tolerated, induced broad and durable anti-RSV antibody and T cell responses, and may be effective in preventing RSV is an important mucosal immune response


    References:

    [1] Bavarian Nordic Announces Breakthrough Therapy Designation For Its Rsv Vaccine Candidate For The Prevention Of Respiratory Syncytial Virus In Older Adults.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.